News stories about MEDNAX (NYSE:MD) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. MEDNAX earned a news impact score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.9775895615722 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Zacks: Analysts Expect MEDNAX Inc (MD) Will Announce Quarterly Sales of $886.36 Million (americanbankingnews.com)
- Trending Stocks in Review: MEDNAX, Inc. (NYSE:MD), Prospect … – The Oracle Examiner (oracleexaminer.com)
- Stock Watch Evaluation – MEDNAX Inc (NYSE: MD) – Alpha Beta … – Alpha Beta Stock (alphabetastock.com)
- Recent Insiders Bustle: Northern Oil and Gas, Inc. (NOG), MEDNAX, Inc. (MD) – Market Movers (financialqz.com)
- The Providence Service (PRSC) and MEDNAX (MD) Financial Comparison (americanbankingnews.com)
Several analysts have recently commented on the stock. SunTrust Banks set a $55.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a research report on Thursday, December 21st. Piper Jaffray Companies assumed coverage on shares of MEDNAX in a research report on Wednesday, December 13th. They set an “overweight” rating and a $58.00 price objective for the company. Jefferies Group reaffirmed a “hold” rating and set a $46.00 price objective on shares of MEDNAX in a research report on Tuesday, October 3rd. KeyCorp set a $51.00 price objective on shares of MEDNAX and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, Citigroup reduced their price objective on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $53.82.
MEDNAX (NYSE:MD) traded up $1.72 during midday trading on Friday, reaching $53.52. 727,436 shares of the company traded hands, compared to its average volume of 737,207. MEDNAX has a twelve month low of $40.56 and a twelve month high of $72.13. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. The firm has a market cap of $5,012.42, a P/E ratio of 18.91, a P/E/G ratio of 1.61 and a beta of 0.39.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.87. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The business had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. During the same quarter last year, the firm posted $1.09 EPS. MEDNAX’s revenue was up 4.9% compared to the same quarter last year. sell-side analysts anticipate that MEDNAX will post 3.1 EPS for the current fiscal year.
In other MEDNAX news, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the transaction, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at $1,834,649.02. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact MEDNAX (MD) Share Price” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://ledgergazette.com/2018/01/22/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-mednax-md-share-price.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.